Skip to main content
Top
Published in: Journal of General Internal Medicine 4/2010

01-04-2010 | Case Reports/Clinical Vignettes

Diabetic Ketoacidosis in Type 2 Diabetics: A Novel Presentation of Pancreatic Adenocarcinoma

Authors: Ming Valerie Lin, MD, Gene Bishop, MD, Maria Benito-Herrero, MD

Published in: Journal of General Internal Medicine | Issue 4/2010

Login to get access

Abstract

Diabetic ketoacidosis (DKA) has been the hallmark of a life-threatening medical emergency for poorly controlled or newly diagnosed type 1 diabetics. In the last two decades, this traditional association has been challenged with increasing reports of type 2 diabetics presenting with DKA. We report the case of a 75-year-old woman with known type 2 diabetes who presented in DKA and was found to have pancreatic adenocarcinoma. A link between diabetes mellitus and pancreatic cancer has been investigated, but the literature remains inconclusive as to whether diabetes mellitus (DM) is a cause or result of pancreatic cancer or simply the confluence of two common entities. Previous case reports of pancreatic tumors presenting with DKA all represented neuroendocrine tumors. Adenocarcinoma of the pancreas should be considered in the list of precipitants for DKA in type 2 DM.
Literature
1.
go back to reference Westphal SA. The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults. Am J Med. 1996;101(1):19–24.CrossRefPubMed Westphal SA. The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults. Am J Med. 1996;101(1):19–24.CrossRefPubMed
2.
go back to reference Linfoot P, Bergstrom C, Ipp E. Pathophysiology of ketoacidosis in Type 2 diabetes mellitus. Diabet Med. 2005;22(10):1414–9.CrossRefPubMed Linfoot P, Bergstrom C, Ipp E. Pathophysiology of ketoacidosis in Type 2 diabetes mellitus. Diabet Med. 2005;22(10):1414–9.CrossRefPubMed
3.
go back to reference Poitout Vincent. Glucolipotoxicity of the pancreatic cell: myth or reality? Biochem Soc Trans. 2008;36:901–4.CrossRefPubMed Poitout Vincent. Glucolipotoxicity of the pancreatic cell: myth or reality? Biochem Soc Trans. 2008;36:901–4.CrossRefPubMed
4.
go back to reference Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006;144(5):350–7.PubMed Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006;144(5):350–7.PubMed
5.
go back to reference Fenkci SM, Fidan Yaylali G, Sermez Y, Akdam H, Sabir N, Kiraç S. Malign cystic glucagonoma presented with diabetic ketoacidosis: case report with an update. Endocr Relat Cancer. 2005;12(2):449–54.CrossRefPubMed Fenkci SM, Fidan Yaylali G, Sermez Y, Akdam H, Sabir N, Kiraç S. Malign cystic glucagonoma presented with diabetic ketoacidosis: case report with an update. Endocr Relat Cancer. 2005;12(2):449–54.CrossRefPubMed
6.
go back to reference Anthony LB, Sharp SC, May ME. Case report: diabetic ketoacidosis in a patient with glucagonoma. Am J Med Sci. 1995;309(6):326–7.PubMedCrossRef Anthony LB, Sharp SC, May ME. Case report: diabetic ketoacidosis in a patient with glucagonoma. Am J Med Sci. 1995;309(6):326–7.PubMedCrossRef
7.
go back to reference Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273(20):1605–9.CrossRefPubMed Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273(20):1605–9.CrossRefPubMed
8.
go back to reference Yalniz M, Pour PM. Diabetes mellitus: a risk factor for pancreatic cancer? Langenbeck’s Arch Surg. 2005;390(1):66–72.CrossRef Yalniz M, Pour PM. Diabetes mellitus: a risk factor for pancreatic cancer? Langenbeck’s Arch Surg. 2005;390(1):66–72.CrossRef
9.
go back to reference Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076–83.CrossRefPubMed Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076–83.CrossRefPubMed
10.
go back to reference Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95–101. Epub 2007 Oct 26. Comment in: Gastroenterology. 2008 Jan;134(1):344–5.CrossRefPubMed Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95–101. Epub 2007 Oct 26. Comment in: Gastroenterology. 2008 Jan;134(1):344–5.CrossRefPubMed
11.
go back to reference Fisher WE, Boros LG, Schirmer WJ. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res. 1996;63(1):310–3.CrossRefPubMed Fisher WE, Boros LG, Schirmer WJ. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res. 1996;63(1):310–3.CrossRefPubMed
12.
go back to reference Fisher WE, Boros LG, Schirmer WJ. Reversal of enhanced pancreatic cancer growth in diabetes by insulin. Surgery. 1995;118(2):453–7. discussion 457–8.CrossRefPubMed Fisher WE, Boros LG, Schirmer WJ. Reversal of enhanced pancreatic cancer growth in diabetes by insulin. Surgery. 1995;118(2):453–7. discussion 457–8.CrossRefPubMed
13.
go back to reference Pour PM, Stepan K. of pancreatic carcinogenesis in the hamster model. VIII. Inhibitory effect of exogenous insulin. J Natl Cancer Inst. 1984;72(5):1205–8.PubMed Pour PM, Stepan K. of pancreatic carcinogenesis in the hamster model. VIII. Inhibitory effect of exogenous insulin. J Natl Cancer Inst. 1984;72(5):1205–8.PubMed
14.
go back to reference Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. Mol Cancer. 2003;2:4.CrossRefPubMed Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. Mol Cancer. 2003;2:4.CrossRefPubMed
15.
go back to reference Cersosimo E, Pisters PW, Pesola G, McDermott K, Bajorunas D, Brennan MF. Insulin secretion and action in patients with pancreatic cancer. Cancer. 1991;67(2):486–93.CrossRefPubMed Cersosimo E, Pisters PW, Pesola G, McDermott K, Bajorunas D, Brennan MF. Insulin secretion and action in patients with pancreatic cancer. Cancer. 1991;67(2):486–93.CrossRefPubMed
16.
go back to reference Basso D, Plebani M, Fogar P, et al. Beta-cell function in pancreatic adenocarcinoma. Pancreas. 1994;9(3):332–5.CrossRefPubMed Basso D, Plebani M, Fogar P, et al. Beta-cell function in pancreatic adenocarcinoma. Pancreas. 1994;9(3):332–5.CrossRefPubMed
17.
go back to reference Liu J, Knezetic JA, Strömmer L, Permert J, Larsson J, Adrian TE. The intracellular mechanism of insulin resistance in pancreatic cancer patients. J Clin Endocrinol Metab. 2000;85(3):1232–8.CrossRefPubMed Liu J, Knezetic JA, Strömmer L, Permert J, Larsson J, Adrian TE. The intracellular mechanism of insulin resistance in pancreatic cancer patients. J Clin Endocrinol Metab. 2000;85(3):1232–8.CrossRefPubMed
18.
go back to reference Mustafa C, Ramiz C, Bayram F, et al. High prevalence of diabetes in patients with pancreatic cancer in central Anatolia, Turkey. Diabetes Res Clin Pract. 2002;58:97–100.CrossRef Mustafa C, Ramiz C, Bayram F, et al. High prevalence of diabetes in patients with pancreatic cancer in central Anatolia, Turkey. Diabetes Res Clin Pract. 2002;58:97–100.CrossRef
19.
go back to reference Slezak L, Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg. 2001;25:452–60.CrossRefPubMed Slezak L, Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg. 2001;25:452–60.CrossRefPubMed
20.
go back to reference Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest. 1983;71(6):1544–53.CrossRefPubMed Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest. 1983;71(6):1544–53.CrossRefPubMed
21.
go back to reference Cersosimo E, Pisters PW, Pesola G, et al. Insulin secretion and action in patients with pancreatic cancer. Cancer. 1991;67:486–93.CrossRefPubMed Cersosimo E, Pisters PW, Pesola G, et al. Insulin secretion and action in patients with pancreatic cancer. Cancer. 1991;67:486–93.CrossRefPubMed
22.
go back to reference Fox JN, Frier BM, Armitage M, Ashby JP. Abnormal insulin secretion in carcinoma of the pancreas: response to glucagon stimulation. Diabet Med. 1985;2:113–6.CrossRefPubMed Fox JN, Frier BM, Armitage M, Ashby JP. Abnormal insulin secretion in carcinoma of the pancreas: response to glucagon stimulation. Diabet Med. 1985;2:113–6.CrossRefPubMed
23.
go back to reference Basso D, Greco E, Fogar P, et al. Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications. Clin Chim Acta. 2005;357:184–9.CrossRefPubMed Basso D, Greco E, Fogar P, et al. Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications. Clin Chim Acta. 2005;357:184–9.CrossRefPubMed
24.
go back to reference Basso D, Valerio A, Brigato L, Panozzo MP, Miola M, Lucca T, Ujka F, Zaninotto M, Avogaro A, Plebani M. An unidentified pancreatic cancer cell product alters some intracellular pathways of glucose metabolism in isolated rat hepatocytes. Pancreas. 1997;15(2):132–8.CrossRefPubMed Basso D, Valerio A, Brigato L, Panozzo MP, Miola M, Lucca T, Ujka F, Zaninotto M, Avogaro A, Plebani M. An unidentified pancreatic cancer cell product alters some intracellular pathways of glucose metabolism in isolated rat hepatocytes. Pancreas. 1997;15(2):132–8.CrossRefPubMed
25.
go back to reference Basso D, Brigato L, Veronesi A, Panozzo MP, Amadori A, Plebani M. The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res. 1995;15(6B):2585–8.PubMed Basso D, Brigato L, Veronesi A, Panozzo MP, Amadori A, Plebani M. The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res. 1995;15(6B):2585–8.PubMed
26.
go back to reference Permert J, Adrian TE, Jacobsson P, Jorfelt L, Fruin AB, Larsson J. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am J Surg. 1993;165(1):61–6. discussion 66–7.CrossRefPubMed Permert J, Adrian TE, Jacobsson P, Jorfelt L, Fruin AB, Larsson J. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am J Surg. 1993;165(1):61–6. discussion 66–7.CrossRefPubMed
27.
go back to reference Nakamori S, Ishikawa O, Ohigashi H, et al. Increased blood proinsulin and decreased C-peptide levels in patients with pancreatic cancer. Hepatogastroenterology. 1999;46(25):16–24.PubMed Nakamori S, Ishikawa O, Ohigashi H, et al. Increased blood proinsulin and decreased C-peptide levels in patients with pancreatic cancer. Hepatogastroenterology. 1999;46(25):16–24.PubMed
28.
go back to reference Ding X, Flatt PR, Permert J, Adrian TE. Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology. 1998;114(1):130–8.CrossRefPubMed Ding X, Flatt PR, Permert J, Adrian TE. Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology. 1998;114(1):130–8.CrossRefPubMed
Metadata
Title
Diabetic Ketoacidosis in Type 2 Diabetics: A Novel Presentation of Pancreatic Adenocarcinoma
Authors
Ming Valerie Lin, MD
Gene Bishop, MD
Maria Benito-Herrero, MD
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 4/2010
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-009-1237-9

Other articles of this Issue 4/2010

Journal of General Internal Medicine 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.